S-5 Capital:

Fundamentally

Different Private Equity

Focused on Supply Chain Materials
Enabling Life Science Products and Services and Specialty Materials.

Laboratory assistants in uniform and protective glasses working with test tubes in the medical laboratory.

About our Firm

Our name “S-5 Capital” is derived from the Japanese vision for Society 5.0 driven by personalized digitalization and advances in Life Science, fully incorporating the technological innovations of the fourth industrial revolution.

Focus

Our Focus is on investing in materials, consumables and service companies in markets ranging from Human Health, Pharma and Applied Markets such as Food Safety, Personal Care, Functional Cosmetics and Nutrition/Wellness.

Mission Critical

Leveraging our teams decades of experience in the space, S-5 seeks to invest in companies providing “Mission Critical” consumables and materials in the Life Sciences supply chain as well as transformational “Hybrid” opportunities that started as traditional Specialty Materials Companies.

We aim to accelerate growth while building sustainable value through:

  • strategic positioning
  • operational focus
  • commercial excellence
  • technology and innovation
  • tactical M&A
  • digital transformation
  • Medical in lab coat holding test tube with drop of color liquid over glass equipment working at the laboratory.
  • Binary pump in HPLC system. High performance liquid chromatography at analytical chemistry laboratory.
  • Young woman applying serum on her face.
  • A closeup of vaccine vials.
Life Sciences are at the forefront of developing the next evolutionary step in society through promoting health and wellness sustainable development goals (SDG).

The S-5 Capital Difference

Unique Investment Approach: Supply Chain Focus into high growth Lifesciences and Specialty Materials Markets:

Result
01

“De-coupling” investment risk from technology risk in Lifesciences allows Investors to uniquely participate in secular growth dynamics.

Result
02

Ability to draw from target companies that are not pure-plays today provides exceptional value arbitrage opportunities.

Result
03

Repositioning and combination of target companies creates a multitude of attractive exit solutions for fund portfolio.

Experience and Team

Significant Industry, Operating and Investment Backgrounds with Broad Global Experience:

Core partners, balanced evenly across the Atlantic, have been around the Life Sciences and Specialty Materials Industry as well as one another for decades and provide homogenous and seamless sourcing and execution capabilities.

Experience

Our team has spent their careers in the sector and bring more than 100 years of collective experience.

Team Lever

  1. Unique mix of financial, transaction and operational experience

.
  2. Core team has “grown up” in the industry and has extensive relationships with company owners, first-tier decision makers and financial sponsors that equips S-5 with partnership and advice in multiple forms of capacity.
  • Female sky diver in helicopter checking for exit over mountain.
  • Skydivers friends having fun.

+

has over 100 years of sector industry experience and involved in over US$100 billion of deal volume

+

sourced and executed more than 50 transactions in the last 5 years alone

+

maintains an actionable S-5 pipeline of 20 plus target companies